Article Versions Notes

Chen P-H, Jhou H-J, Chung C-H, Wu Y-Y, Huang T-C, Lee C-H, Chien W-C, Chen J-H. Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer. Medicina. 2023; 59(1):10. https://doi.org/10.3390/medicina59010010

Chen, Po-Huang, Hong-Jie Jhou, Chi-Hsiang Chung, Yi-Ying Wu, Tzu-Chuan Huang, Cho-Hao Lee, Wu-Chien Chien, and Jia-Hong Chen. 2023. "Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer" Medicina 59, no. 1: 10. https://doi.org/10.3390/medicina59010010

Chen, P.-H., Jhou, H.-J., Chung, C.-H., Wu, Y.-Y., Huang, T.-C., Lee, C.-H., Chien, W.-C., & Chen, J.-H. (2023). Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer. Medicina, 59(1), 10. https://doi.org/10.3390/medicina59010010